Navigating the Myriad of Systemic Treatment Choices for Severe Atopic Dermatitis in a Post Covid-19 Era

Conventional agents include CsA, MTX and MMF. These have broad immunosuppressive effects and exhaustive adverse effect profiles. These are being slowly replaced by newer agents that are targeted and more specific, such as JAK inhibitors and dupilumab. Adjunctive treatments (including prednisolone and nbUVB) will likely continue to have a role in managing some atopic dermatitis presentations. This talk compares available and upcoming systemic treatment options and provides practical guidance to help patients and their treating doctors make informed treatment choices.

Scroll to Top